IP Library Granted Patent US 11,584,760
Granted Patent B2
US 11,584,760 · App. 17/030,073 · Granted Feb 21, 2023

Dithio ETP derivatives

Inventors: Sangkil Nam (Tujunga, CA); David Horne (Altadena, CA); Larry Eugene Overman (Corona Del Mar, CA); Brad Loertscher (Portage, MI)
Assignees: CITY OF HOPE; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
C07D513/18A61K31/548A61K31/706A61K45/06A61P35/00C07D401/12C07D487/04C07D513/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,584,760
App. No.
17/030,073
Granted
Feb 21, 2023
Kind
B2
Abstract

Disclosed herein, inter alia, are compositions and methods of using the same for the treatment of cancer.

Claims (53)

1. A compound having the formula (III):

or a pharmaceutically acceptable salt thereof,

wherein:

X 1 is N or CR 10 ;

X 2 is N or CR 11 ;

X 3 is N or CR 12 ;

R 1.1 is hydrogen, halogen, —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —COOR 1.1A , —CONR 1.1B R 1.1C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1.2 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 ,—CI 3 , —CN, —CHO, —OR 1.2A , —NR 1.2B R 1.2C , —COOR 1.2A , —CONR 1.2B R 1.2C , —NO 2 , —SR 1.2D , —SO n1.2 R 1.2B , —SO v1.2 NR 1.2B R 1.2C , —NHNR 1.2B R 1.2C , —ONR 1.2B R 1.2C , —NHC(O)NHNR 1.2B R 1.2C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1.3 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 1.3A , —NR 1.3B R 1.3C , —COOR 1.3A , —CONR 1.3B R 1.3C , —NO 2 , —SR 1.3D , —SO n1.3 R 1.3B , —SO v1.3 NR 1.3B R 1.3C , —NHNR 1.3B R 1.3C , —ONR 1.3B R 1.3C , —NHC(O)NHNR 1.3B R 1.3C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1.4 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 1.4A , —NR 1.4B R 1.4C , —COOR 1.4A , —CONR 1.4B R 1.4C , —NO 2 , —SR 1.4D , —SO n1.4 R 1.4B , —SO v1.4 NR 1.4B R 1.4C , —NHNR 1.4B R 1.4C , —ONR 1.4B R 1.4C , —NHC(O)NHNR 1.4B R 1.4C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1.5 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 1.5A , —NR 1.5B R 1.5C , —COOR 1.5A , —CONR 1.5B R 1.5C , —NO 2 , —SR 1.5D , —SO n1.5 R 1.5B , —SO v1.5 NR 1.5B R 1.5C , —NHNR 1.5B R 1.5C , —ONR 1.5B R 1.5C , —NHC(O)NHNR 1.5B R 1.5C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 2 is hydrogen, —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —COOR 2A , —CONR 2B R 2C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 3 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 3A , —NR 3B R 3C , —COOR 3A , —CONR 3B R 3C , —NO 2 , —SR 3D , —SO n3 R 3B , —SO v3 NR 3B R 3C , —NHNR 3B R 3C , —ONR 3B R 3C , —NHC(O)NHNR 3B R 3C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 4 is —C(O)-L 1 -R 18 ;

R 5 is —C(O)-L 2 -R 19 ;

L 1 is a bond;

L 2 is a bond;

R 18 and R 19 are independently unsubstituted C 1 -C 3 alkyl;

R 6 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 6A , —NR 6B R 6C , —COOR 6A , —CONR 6B R 6C , —NO 2 , —SR 6D , —SO n6 R 6B , —SO v6 NR 6B R 6C , —NHNR 6B R 6C , —ONR 6B R 6C , —NHC(O)NHNR 6B R 6C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 7 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 7A , —NR 7B R 7C , —COOR 7A , —CONR 7B R 7C , —NO 2 , —SR 7D , —SO n7 R 7B , —SO v7 NR 7B R 7C , —NHNR 7B R 7C , —ONR 7B R 7C , —NHC(O)NHNR 7B R 7C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 10 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 10A , —NR 10B R 10C , —COOR 10A , —CONR 10B R 10C , —NO 2 , —SR 10D , —SO n10 R 10B , —SO v10 NR 10B R 10C , —NHNR 10B R 10C , —ONR 10B R 10C , —NHC(O)NHNR 10B R 10C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 11 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 11A , —NR 11B R 11C , —COOR 11A , —CONR 11B R 11C , —NO 2 , —SR 11D , —SO n11 R 11B , —SO v11 NR 11B R 11C , —NHNR 11B R 11C , —ONR 11B R 11C , —NHC(O)NHNR 11B R 11C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 10 and R 11 may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl;

R 12 is hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OR 12A , —NR 12B R 12C , —COOR 12A , —CONR 12B R 12C , —NO 2 , —SR 12D , —SO n12 R 12B , —SO v12 NR 12B R 12C , —NHNR 12B R 12C , —ONR 12B R 12C , —NHC(O)NHNR 12B R 12C , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 11 and R 12 may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl;

R 1.1A , R 1.1B , R 1.1C , R 1.2A , and R 1.2B , R 1.2C , R 1.2D , R 1.3A , R 1.3B , and R 1.3C , R 1.3D , R 1.4A , R 1.4B , R 1.4C , R 1.4D , R 1.5A , R 1.5B , R 1.5C , and R 1.5D are independently hydrogen, halogen, —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)—OH, —NHOH, —OCF 3 , —OCCl 3 , —OCBr 3 , —OCI 3 , —OCHF 2 , —OCHCl 2 , —OCHBr 2 , —OCHI 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R 1.1B and R 1.1C , R 1.2B and R 1.2C , R 1.3B and R 1.3C , R 1.4B and R 1.4C , and R 1.5B and R 1.5C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;

R 2A , R 2B , R 2C , R 3A , R 3B , R 3C , R 3D , R 6A , R 6B , R 6C , R 6D , R 7A , R 7B , R 7C , R 7D , R 10A , R 10B , R 10C , R 10D , R 11A , R 11B , R 11C , R 11D , R 12A , R 12B , R 12C , and R 12D are independently hydrogen, halogen, —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)—OH, —NHOH, —OCF 3 , —OCCl 3 , —OCBr 3 , —OCI 3 , —OCHF 2 , —OCHCl 2 , —OCHBr 2 , —OCHI 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R 6B and R 6C , R 7B and R 7C , R 10B and R 10C , R 11B and R 11C , and R 12B and R 12C , substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;

n1.2, n1.3, n1.4, n1.5, n3, n6, n7, n10, n11 and n12 are independently an integer from 0 to 4; and

v1.2, v1.3, v1.4, v1.5, v3, v6, v7, v10, v11 and v12, are independently 1 or 2.

2. The compound of claim 1 , wherein the compound has the structure of Formula (IV):

3. The compound of claim 1 , wherein R 10 and R 11 or R 11 and R 12 are joined to form a substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl having structural formula:

wherein:

X 6 is O, NR 23A , or S;

X 7 is O, NR 24A , or S;

z4 is an integer from 0 to 2;

z5 is an integer from 0 to 8;

m is 1 or 2; and

R 21 , R 22 , R 23A , and R 24A are each independently hydrogen, halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl 3 , —OCF 3 , —OCBr 3 , —OCI 3 , —OCHCl 2 , —OCHBr 2 , —OCHI 2 , —OCHF 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

4. The compound of claim 2 , wherein the compound has the formula:

5. The compound of claim 3 , wherein the compound has the formula:

6. The compound of claim 5 , wherein the compound has the formula:

7. The compound of claim 1 , wherein R 6 and R 7 are each independently hydrogen.

8. The compound of claim 1 , wherein X 2 is N.

9. The compound of claim 1 , wherein R 12 is halogen or —OR 12A .

10. The compound of claim 1 , wherein R 1.2 is substituted or unsubstituted alkyl.

11. The compound of claim 1 , wherein R 1.3 is —CN.

12. The compound of claim 1 , wherein R 2 is substituted or unsubstituted alkyl.

13. The compound of claim 1 , wherein the compound has the structure:

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

15. A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein the cancer is lymphoma, melanoma, prostate cancer, or lung cancer.

16. The method of claim 15 , further comprising administering at least one additional anticancer agent, wherein the additional anticancer agent comprises an epigenetic inhibitor or a multi-kinase inhibitor.

17. The method of claim 16 , wherein the epigenetic inhibitor is azacitidine or decitadine and the multi-kinase inhibitor is sorafenib.

18. A method of inhibiting the growth of a cancer cell, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , wherein the cancer cell is lymphoma cell, melanoma cell, lung cancer cell, or prostate cancer cell.

19. The method of claim 18 , wherein lymphoma is cutaneous T-cell lymphoma.

Assignments (3)
CONFIRMATORY LICENSE Recorded Oct 12, 2022
From: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061656/0698 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2021
From: NAM, SANGKIL; HORNE, DAVID
To: CITY OF HOPE
Reel/Frame 057881/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2021
From: OVERMAN, LARRY EUGENE; LOERTSCHER, BRAD
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 057881/0850 →
Continuity (4)
Continuation 16333577
Provisional Application 62433678 · Dec 13, 2016
Provisional Application 62395244 · Sep 15, 2016
Related Publication 20210115066A1 · Apr 22, 2021